<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36499097</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>23</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">14769</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms232314769</ELocationID><Abstract><AbstractText>The use of cellular models is a common means to investigate the potency of therapeutics in pre-clinical drug discovery. However, there is currently no consensus on which model most accurately replicates key aspects of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) pathology, such as accumulation of insoluble, cytoplasmic transactive response DNA-binding protein (TDP-43) and the formation of insoluble stress granules. Given this, we characterised two TDP-43 proteinopathy cellular models that were based on different aetiologies of disease. The first was a sodium arsenite-induced chronic oxidative stress model and the second expressed a disease-relevant TDP-43 mutation (TDP-43 M337V). The sodium arsenite model displayed most aspects of TDP-43, stress granule and ubiquitin pathology seen in human ALS/FTD donor tissue, whereas the mutant cell line only modelled some aspects. When these two cellular models were exposed to small molecule chemical probes, different effects were observed across the two models. For example, a previously disclosed sulfonamide compound decreased cytoplasmic TDP-43 and increased soluble levels of stress granule marker TIA-1 in the cellular stress model without impacting these levels in the mutant cell line. This study highlights the challenges of using cellular models in lead development during drug discovery for ALS and FTD and reinforces the need to perform assessments of novel therapeutics across a variety of cell lines and aetiological models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Hei W A</ForeName><Initials>HWA</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callis</LastName><ForeName>Timothy B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-1819-3619</Identifier><AffiliationInfo><Affiliation>School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danon</LastName><ForeName>Jonathan J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-6242-1941</Identifier><AffiliationInfo><Affiliation>School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorgensen</LastName><ForeName>William T</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Yazi D</ForeName><Initials>YD</Initials><Identifier Source="ORCID">0000-0002-1423-0451</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, 2 Technology Place, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ittner</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, 2 Technology Place, Macquarie University, Sydney, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werry</LastName><ForeName>Eryn L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassiou</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW 2006, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>APP1132524, APP1154692, GNT2008066</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>48OVY2OC72</RegistryNumber><NameOfSubstance UI="C017947">sodium arsenite</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">proteinopathy</Keyword><Keyword MajorTopicYN="N">stress granules</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36499097</ArticleId><ArticleId IdType="pmc">PMC9738080</ArticleId><ArticleId IdType="doi">10.3390/ijms232314769</ArticleId><ArticleId IdType="pii">ijms232314769</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Bigio E.H., Ince P.G., Geser F., Neumann M., Cairns N.J., Kwong L.K., Forman M.S., Ravits J., Stewart H. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S., Wheeler J.R., Walters R.W., Agrawal A., Barsic A., Parker R. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell. 2016;164:487&#x2013;498. doi: 10.1016/j.cell.2015.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.12.038</ArticleId><ArticleId IdType="pmc">PMC4733397</ArticleId><ArticleId IdType="pubmed">26777405</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., Gomes E., Guo L., Mojsilovic-Petrovic J., Tran V., Kalb R.G., Shorter J., Bonini N.M. Poly (ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol. Cell. 2018;71:703&#x2013;717. doi: 10.1016/j.molcel.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P., Kedersha N. Visibly stressed: The role of eIF2, TIA-1, and stress granules in protein translation. Cell Stress Chaperones. 2002;7:213. doi: 10.1379/1466-1268(2002)007&lt;0213:VSTROE&gt;2.0.CO;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1379/1466-1268(2002)007&lt;0213:VSTROE&gt;2.0.CO;2</ArticleId><ArticleId IdType="pmc">PMC514820</ArticleId><ArticleId IdType="pubmed">12380690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Q., Chaplin J., Morris M.J., Hilliard M.A., Wolvetang E., Ng D.C.H., Noakes P.G. TDP-43 Mutation Affects Stress Granule Dynamics in Differentiated NSC-34 Motoneuron-Like Cells. Front. Cell Neurosci. 2021;9:611601. doi: 10.3389/fcell.2021.611601.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.611601</ArticleId><ArticleId IdType="pmc">PMC8217991</ArticleId><ArticleId IdType="pubmed">34169068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E., Neumann M., Tahirovic S., Rodde R., Dormann D., Haass C. Requirements for stress granule recruitment of fused in Sarcoma (FUS) and TAR DNA binding protein of 43 kDa (TDP-43) J. Biol. Chem. 2012;287:23079&#x2013;23094. doi: 10.1074/jbc.M111.328757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.328757</ArticleId><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M., Han T.W., Xie S., Shi K., Du X., Wu L.C., Mirzaei H., Goldsmith E.J., Longgood J., Pei J. Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767. doi: 10.1016/j.cell.2012.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.04.017</ArticleId><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A., Temirov J., Lee J., Coughlin M., Kanagaraj A.P., Kim H.J., Mittag T., Taylor J.P. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133. doi: 10.1016/j.cell.2015.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.09.015</ArticleId><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz J., Parker S.J., Vella L.J., Ng D., Price K.A., Liddell J.R., Caragounis A., Li Q.X., Masters C.L., Nonaka T., et al. N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Mol. Neurodegener. 2011;6:1&#x2013;22. doi: 10.1186/1750-1326-6-57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-57</ArticleId><ArticleId IdType="pmc">PMC3162576</ArticleId><ArticleId IdType="pubmed">21819629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A., Gumina V., Lenzi P., Bossolasco P., Fulceri F., Volpe C., Bardelli D., Pregnolato F., Maraschi A., Fornai F., et al. Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol. Dis. 2020;145:105051. doi: 10.1016/j.nbd.2020.105051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105051</ArticleId><ArticleId IdType="pubmed">32827688</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang M.Y., Markmiller S., Vu A.Q., Javaherian A., Dowdle W.E., Jolivet P., Bushway P.J., Castello N.A., Baral A., Chan M.Y. Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS/FTD. Neuron. 2019;103:802&#x2013;819. doi: 10.1016/j.neuron.2019.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.05.048</ArticleId><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Watanabe A., Tsukita K., Woltjen K., Yamamoto T., Hotta A., Kondo T., Kitaoka S., Ohta A., et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaaf3962. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bourgeais J., Bruno C., Hergesheimer R.C., Thepault R.A., Vourc&#x2019;h P., Corcia P., Andres C.R., Herault O., Blasco H. TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol to Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis. Cells. 2019;9:68. doi: 10.3390/cells9010068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010068</ArticleId><ArticleId IdType="pmc">PMC7016571</ArticleId><ArticleId IdType="pubmed">31888078</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald K.K., Aulas A., Destroismaisons L., Pickles S., Beleac E., Camu W., Rouleau G.A., Vande Velde C. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Human Mol. Genet. 2011;20:1400&#x2013;1410. doi: 10.1093/hmg/ddr021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr021</ArticleId><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey C.M., Cenik B., Sephton C.F., Johnson B.A., Herz J., Yu G. TDP-43 aggregation in neurodegeneration: Are stress granules the key? Brain Res. 2012;1462:16&#x2013;25. doi: 10.1016/j.brainres.2012.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.02.032</ArticleId><ArticleId IdType="pmc">PMC3372581</ArticleId><ArticleId IdType="pubmed">22405725</ArticleId></ArticleIdList></Reference><Reference><Citation>Emara M.M., Fujimura K., Sciaranghella D., Ivanova V., Ivanov P., Anderson P. Hydrogen peroxide induces stress granule formation independent of eIF2&#x3b1; phosphorylation. Biochem. Biophys. Res. Commun. 2012;423:763&#x2013;769. doi: 10.1016/j.bbrc.2012.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.06.033</ArticleId><ArticleId IdType="pmc">PMC3399031</ArticleId><ArticleId IdType="pubmed">22705549</ArticleId></ArticleIdList></Reference><Reference><Citation>Palangi F., Samuel S.M., Thompson I.R., Triggle C.R., Emara M.M. Effects of oxidative and thermal stresses on stress granule formation in human induced pluripotent stem cells. PLoS ONE. 2017;12:e0182059. doi: 10.1371/journal.pone.0182059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182059</ArticleId><ArticleId IdType="pmc">PMC5528897</ArticleId><ArticleId IdType="pubmed">28746394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer B., Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA. 1988;85:5166&#x2013;5170. doi: 10.1073/pnas.85.14.5166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.14.5166</ArticleId><ArticleId IdType="pmc">PMC281709</ArticleId><ArticleId IdType="pubmed">2839833</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.X., Athar M., Lippai I., Waldren C., Hei T.K. Induction of oxyradicals by arsenic: Implication for mechanism of genotoxicity. Proc. Natl. Acad. Sci. USA. 2001;98:1643&#x2013;1648. doi: 10.1073/pnas.98.4.1643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.4.1643</ArticleId><ArticleId IdType="pmc">PMC29310</ArticleId><ArticleId IdType="pubmed">11172004</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L., Bilgutay A., Zhang Y.-J., Vanderwyde T., Citro A., Mehta T., Zaarur N., McKee A., Bowser R., Sherman M. Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250. doi: 10.1371/journal.pone.0013250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihevc S.P., Baralle M., Buratti E., Rogelj B. TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci. Rep. 2016;6:33996. doi: 10.1038/srep33996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33996</ArticleId><ArticleId IdType="pmc">PMC5036055</ArticleId><ArticleId IdType="pubmed">27665936</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y., Kelley T., Mackenzie I.R., Pickering-Brown S., Du Plessis D., Neary D., Snowden J.S., Mann D.M. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta. Neuropathol. 2007;113:521&#x2013;533. doi: 10.1007/s00401-006-0189-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0189-y</ArticleId><ArticleId IdType="pubmed">17219193</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns N.J., Neumann M., Bigio E.H., Holm I.E., Troost D., Hatanpaa K.J., Foong C., White III C.L., Schneider J.A., Kretzschmar H.A. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 2007;171:227&#x2013;240. doi: 10.2353/ajpath.2007.070182.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070182</ArticleId><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkening K., Leystra-Lantz C., Yang W., Jaffee H., Strong M.J. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS) Brain Res. 2009;1305:168&#x2013;182. doi: 10.1016/j.brainres.2009.09.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.09.105</ArticleId><ArticleId IdType="pubmed">19815002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D.-Y., Jeon G.S., Sung J.-J. ALS-linked mutant SOD1 associates with TIA-1 and alters stress granule dynamics. Neurochem. Res. 2020;45:2884&#x2013;2893. doi: 10.1007/s11064-020-03137-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-020-03137-5</ArticleId><ArticleId IdType="pubmed">33025330</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita K., Ito H., Nakano S., Kinoshita Y., Wate R., Kusaka H. Immunohistochemical identification of messenger RNA-related proteins in basophilic inclusions of adult-onset atypical motor neuron disease. Acta. Neuropathol. 2008;116:439&#x2013;445. doi: 10.1007/s00401-008-0415-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0415-x</ArticleId><ArticleId IdType="pubmed">18642007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio E.H., Johnson N.A., Rademaker A.W., Fung B.B., Mesulam M.-M., Siddique N., Dellefave L., Caliendo J., Freeman S., Siddique T. Neuronal ubiquitinated intranuclear inclusions in familial and non-familial frontotemporal dementia of the motor neuron disease type associated with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2004;63:801&#x2013;811. doi: 10.1093/jnen/63.8.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.8.801</ArticleId><ArticleId IdType="pubmed">15330335</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez de Silanes I., Galb&#xe1;n S., Martindale J.L., Yang X., Mazan-Mamczarz K., Indig F.E., Falco G., Zhan M., Gorospe M. Identification and functional outcome of mRNAs associated with RNA-binding protein TIA-1. Mol. Cell. Biol. 2005;25:9520&#x2013;9531. doi: 10.1128/MCB.25.21.9520-9531.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.21.9520-9531.2005</ArticleId><ArticleId IdType="pmc">PMC1265820</ArticleId><ArticleId IdType="pubmed">16227602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.-C., Albuquerque C.P., Han J.S., Lagier-Tourenne C., Tokunaga S., Zhou H., Cleveland D.W. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. USA. 2010;107:13318&#x2013;13323. doi: 10.1073/pnas.1008227107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1008227107</ArticleId><ArticleId IdType="pmc">PMC2922163</ArticleId><ArticleId IdType="pubmed">20624952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Lin L., Tradewell M.L., Dion P.A., Bercier V., Bourgouin P., Rochefort D., Bel Hadj S., Durham H.D., Velde C.V. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2009;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Deng J., Dong J., Liu J., Bigio E.H., Mesulam M., Wang T., Sun L., Wang L., Lee A.Y.-L. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd J.D., Lee-Armandt J.P., Feiler M.S., Zaarur N., Liu M., Kraemer B., Concannon J.B., Ebata A., Wolozin B., Glicksman M.A. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J. Biomol. Screen. 2014;19:44&#x2013;56. doi: 10.1177/1087057113501553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1087057113501553</ArticleId><ArticleId IdType="pmc">PMC3913261</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A., Polymenidou M. Mammalian Prion Biology: One Century of Evolving Concepts. Cell. 2004;116:313&#x2013;327. doi: 10.1016/S0092-8674(03)01031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)01031-6</ArticleId><ArticleId IdType="pubmed">14744440</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilks N., Kedersha N., Ayodele M., Shen L., Stoecklin G., Dember L.M., Anderson P. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol. Biol. Cell. 2004;15:5383&#x2013;5398. doi: 10.1091/mbc.e04-08-0715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e04-08-0715</ArticleId><ArticleId IdType="pmc">PMC532018</ArticleId><ArticleId IdType="pubmed">15371533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazroui R., Di Marco S., Kaufman R.J., Gallouzi I.-E. Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol. Biol. Cell. 2007;18:2603&#x2013;2618. doi: 10.1091/mbc.e06-12-1079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e06-12-1079</ArticleId><ArticleId IdType="pmc">PMC1924830</ArticleId><ArticleId IdType="pubmed">17475769</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwon Y., Maxwell B.A., Kolaitis R.-M., Zhang P., Kim H.J., Taylor J.P. Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner. Science. 2021;372:eabf6548. doi: 10.1126/science.abf6548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6548</ArticleId><ArticleId IdType="pmc">PMC8574224</ArticleId><ArticleId IdType="pubmed">34739333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler J.R., Matheny T., Jain S., Abrisch R., Parker R. Distinct stages in stress granule assembly and disassembly. eLife. 2016;5:e18413. doi: 10.7554/eLife.18413.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.18413</ArticleId><ArticleId IdType="pmc">PMC5014549</ArticleId><ArticleId IdType="pubmed">27602576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Nicholson A.M., Sarkar M., Messing J., Purice M.D., Pottier C., Annu K., Baker M., Perkerson R.B., Kurti A. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95:808&#x2013;816. doi: 10.1016/j.neuron.2017.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eersel J., Ke Y.D., Gladbach A., Bi M., G&#xf6;tz J., Kril J.J., Ittner L.M. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS ONE. 2011;6:e22850. doi: 10.1371/journal.pone.0022850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022850</ArticleId><ArticleId IdType="pmc">PMC3146516</ArticleId><ArticleId IdType="pubmed">21829535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T., Kawakami E., Endo K., Misawa H., Watabe K. Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging. PLoS ONE. 2017;12:e0179375. doi: 10.1371/journal.pone.0179375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179375</ArticleId><ArticleId IdType="pmc">PMC5466347</ArticleId><ArticleId IdType="pubmed">28599005</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M.J., Igaz L.M., Wong M.M., Kwong L.K., Trojanowski J.Q., Lee V.M. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A.S., Chun C., Hesson J., Mathieu J., Valdmanis P.N., Mack D.L., Choi B.-O., Kim D.-H., Bothwell M. Human Induced Pluripotent Stem Cell-Derived TDP-43 Mutant Neurons Exhibit Consistent Functional Phenotypes Across Multiple Gene Edited Lines Despite Transcriptomic and Splicing Discrepancies. Front. Cell Neurosci. 2021;9:728707. doi: 10.3389/fcell.2021.728707.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.728707</ArticleId><ArticleId IdType="pmc">PMC8511491</ArticleId><ArticleId IdType="pubmed">34660586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Huang E.J. Modeling ALS and FTD with iPSC-derived neurons. Brain Res. 2017;1656:88&#x2013;97. doi: 10.1016/j.brainres.2015.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.10.003</ArticleId><ArticleId IdType="pmc">PMC4833714</ArticleId><ArticleId IdType="pubmed">26462653</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez V., Sridharan V., Sabat&#xe9; S., Villacampa M., Men&#xe9;ndez J.C. Three-Component Synthesis of Pyrrole-Related Nitrogen Heterocycles by a Hantzsch-Type Process: Comparison between Conventional and High-Speed Vibration Milling Conditions. Asian J. Org. Chem. 2016;5:652&#x2013;662. doi: 10.1002/ajoc.201600061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajoc.201600061</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen G.R., Weigele M., Vacca J.P. Preparation of Pyrrolidinecarbonyl-Pyrrole- Sulfonamides Useful in Modulation of the Inclusion Formation Treatment of Diseases. WO2016090313A1. 2016 June 9;</Citation></Reference><Reference><Citation>He G., Chen G. A Practical Strategy for the Structural Diversification of Aliphatic Scaffolds through the Palladium-Catalyzed Picolinamide-Directed Remote Functionalization of Unactivated C(sp3) H Bonds. Angew. Chem. Int. Ed. 2011;50:5192&#x2013;5196. doi: 10.1002/anie.201100984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201100984</ArticleId><ArticleId IdType="pubmed">21538752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon J., Thaker K. Ring&#x2013;chain tautomerism in the acid esters of pyridine-2: 3-dicarboxylic acid. J. Chem. Soc. 1957:2531&#x2013;2536. doi: 10.1039/JR9570002531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/JR9570002531</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>